The other side of the coin: Leveraging Epstein–Barr virus in research and therapy

Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Fenggang, Tan, Wei Jian, Lu, Yanan, MacAry, Paul A., Loh, Kwok Seng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108324/
https://www.ncbi.nlm.nih.gov/pubmed/27531881
http://dx.doi.org/10.1016/j.oraloncology.2016.07.010
_version_ 1783512788347387904
author Yu, Fenggang
Tan, Wei Jian
Lu, Yanan
MacAry, Paul A.
Loh, Kwok Seng
author_facet Yu, Fenggang
Tan, Wei Jian
Lu, Yanan
MacAry, Paul A.
Loh, Kwok Seng
author_sort Yu, Fenggang
collection PubMed
description Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research efforts primarily focused on dissecting the mechanism of EBV-induced oncogenesis. Here, we present an alternate facet of the oncovirus EBV, on its applications in research and therapy. Finally, discussions on the prospective utilization of EBV in nasopharyngeal carcinoma (NPC) diagnosis and therapy will also be presented.
format Online
Article
Text
id pubmed-7108324
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71083242020-03-31 The other side of the coin: Leveraging Epstein–Barr virus in research and therapy Yu, Fenggang Tan, Wei Jian Lu, Yanan MacAry, Paul A. Loh, Kwok Seng Oral Oncol Article Epstein-Barr virus is (EBV) a ubiquitous virus prevalent in 90% of the human population. Transmitted through infected saliva, EBV is the causative agent of infectious mononucleosis (IM) and is further implicated in malignancies of lymphoid and epithelial origins. In the past few decades, research efforts primarily focused on dissecting the mechanism of EBV-induced oncogenesis. Here, we present an alternate facet of the oncovirus EBV, on its applications in research and therapy. Finally, discussions on the prospective utilization of EBV in nasopharyngeal carcinoma (NPC) diagnosis and therapy will also be presented. Elsevier Ltd. 2016-09 2016-07-21 /pmc/articles/PMC7108324/ /pubmed/27531881 http://dx.doi.org/10.1016/j.oraloncology.2016.07.010 Text en © 2016 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Yu, Fenggang
Tan, Wei Jian
Lu, Yanan
MacAry, Paul A.
Loh, Kwok Seng
The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title_full The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title_fullStr The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title_full_unstemmed The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title_short The other side of the coin: Leveraging Epstein–Barr virus in research and therapy
title_sort other side of the coin: leveraging epstein–barr virus in research and therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108324/
https://www.ncbi.nlm.nih.gov/pubmed/27531881
http://dx.doi.org/10.1016/j.oraloncology.2016.07.010
work_keys_str_mv AT yufenggang theothersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT tanweijian theothersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT luyanan theothersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT macarypaula theothersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT lohkwokseng theothersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT yufenggang othersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT tanweijian othersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT luyanan othersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT macarypaula othersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy
AT lohkwokseng othersideofthecoinleveragingepsteinbarrvirusinresearchandtherapy

Ejemplares similares